SIENA, Italy, August 3, 2016 /PRNewswire/ --
Philogen S.p.A. (a privately owned company) today announced that they have entered into a collaboration, option and license agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop a new class of immunomodulatory therapeutics. The agreement was facilitated by Johnson & Johnson Innovation.
"We are extremely pleased to establish a new collaboration with Janssen, an innovative leader in antibody-based approaches for therapeutic intervention of disease processes," commented Dr. Duccio Neri, Philogen's CEO.
No financial details of the agreement were released.
Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit http://www.philogen.com
SOURCE Philogen S.p.A.